Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial
| Autor: | Jayanth R. Arnold, Gerry P McCann, Leong L. Ng, N J Samani, Kamal Chitkara, Florence Y. Lai, Glenn Rodrigo, A P Vanezis, Radek Debiec, Jamal N Khan, John G Coghlan, Simon Hetherington, Sheraz A Nazir |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Ischemia heart failure Context (language use) 030204 cardiovascular system & hematology ventricular remodelling law.invention 03 medical and health sciences Ventricular Dysfunction Left 0302 clinical medicine Percutaneous Coronary Intervention Postoperative Complications Randomized controlled trial law Internal medicine Natriuretic Peptide Brain Outcome Assessment Health Care Natriuretic peptide Medicine Humans remote ischaemic conditioning 030212 general & internal medicine Myocardial infarction cardiovascular diseases Heart Failure and Cardiomyopathies Aged Ejection fraction business.industry Hemodynamic Monitoring Stroke Volume Middle Aged medicine.disease primary percutaneous coronary intervention Peptide Fragments Clinical trial ST elevation myocardial infarction Heart failure Ischemic Preconditioning Myocardial Cardiology cardiovascular system Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Heart |
| ISSN: | 1468-201X |
| Popis: | BackgroundRemote ischaemic conditioning (rIC) is a cardioprotective tool which has shown promise in preclinical and clinical trials in the context of acute ischaemia. Repeated rIC post myocardial infarction may provide additional benefits which have not previously been tested clinically.MethodsThe trial assessed the role of daily rIC in enhancing left ventricular ejection fraction (LVEF) recovery in patients with impaired LVEF (ResultsThe treatment and control groups were well matched at baseline including for mean LVEF (42.8% vs 44.3% respectively, p=0.952). There was no difference in the improvement in LVEF over 4 months between the treatment and control groups (4.8%±7.8% vs 4.6%±5.9% respectively, p=0.924). No differences were seen in the secondary outcome measures including changes in infarct size and left ventricular end-diastolic and systolic volumes, major adverse cardiac and cerebral event, mean Kansas City Cardiomyopathy Questionnaire score and change in N-terminal pro-brain natriuretic peptide levels.ConclusionsDaily rIC starting on day 3 and continued for 4 weeks following successful P-PCI for STEMI did not improve LVEF as assessed by CMR after 4 months when compared with a matched control group.Trial registration numberNCT0166461. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|